SCHEMBL2955258

SCHEMBL2955258

Cc1ccc(S(=O)(=O)Oc2ccc(N3CCC(Oc4ccc(OC(F)(F)F)cc4)CC3)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.48
FPR2 P25090 3/20 0.47
PROKR1 Q8TCW9 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
MAPT P10636 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
LMNA P02545 1/20 0.47
PTGS1 P23219 1/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A4 P31645 1/20 0.46
LIPE Q05469 3/20 0.43
BCHE P06276 1/20 0.43
ACHE P22303 1/20 0.43
MMP13 P45452 2/20 0.43
EPHX1 P07099 1/20 0.43
EPHX2 P34913 1/20 0.43
MMP12 P39900 1/20 0.43
MMP14 P50281 1/20 0.43
MMP2 P08253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2056202 0.88 KCNH2 (0.58) KCNH2FPR2PROKR1MAPTPTGS1
SCHEMBL3038315 0.87 CARM1 (0.49) KCNH2SMN1; SMN2LMNALIPEBCHE
SCHEMBL2955257 0.85 KCNH2 (0.47) KCNH2FPR2PROKR1MEN1KMT2A
SCHEMBL14053224 0.82 KCNH2 (0.47) KCNH2FPR2PROKR1MEN1KMT2A
SCHEMBL2553568 0.81 GPR119 (0.56) KCNH2FPR2PROKR1PTGS1SLC6A2
SCHEMBL12284379 0.81 GPR119 (0.56) KCNH2FPR2PROKR1PTGS1SLC6A2
SCHEMBL15441936 0.80 BCHE (0.47) MEN1KMT2AMAPTSMN1; SMN2LMNA
SCHEMBL2233889 0.80 BCHE (0.57) MEN1KMT2AMAPTSMN1; SMN2LMNA
SCHEMBL2357937 0.79 KCNH2 (0.47) KCNH2FPR2PROKR1PTGS1SLC6A2
SCHEMBL19809288 0.79 KCNH2 (0.47) KCNH2FPR2PROKR1PTGS1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3275862-B1 METHOD FOR PRODUCING 1-(4-HYDROXYPHENYL)-4-(4-TRIFLUOROMETHOXYPHENOXY)PIPERIDINE OR SALT THEREOF OTSUKA PHARMA CO LTD (JP) 2020-08-12 EP disclosed
US-10252995-B2 Method for producing 1-(4-hydroxyphenyl)-4-(4-trifluoromethoxyphenoxy)piperidine or salt thereof OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-04-09 US disclosed
US-20180065931-A1 METHOD FOR PRODUCING 1-(4-HYDROXYPHENYL)-4-(4-TRIFLUOROMETHOXYPHENOXY)PIPERIDINE OR SALT THEREOF OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2018-03-08 US disclosed
EP-3275862-A1 METHOD FOR PRODUCING 1-(4-HYDROXYPHENYL)-4-(4-TRIFLUOROMETHOXYPHENOXY)PIPERIDINE OR SALT THEREOF Otsuka Pharmaceutical Co., Ltd. (JP) 2018-01-31 EP disclosed
EP-1727782-B1 METHOD OF PRODUCING AMINOPHENOL COMPOUNDS OTSUKA PHARMA CO LTD (JP) 2012-08-22 EP disclosed
US-7750156-B2 Method of producing aminophenol compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-07-06 US disclosed
US-20070219374-A1 Method of Producing Aminophenol Compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180065931-A1 METHOD FOR PRODUCING 1-(4-HYDROXYPHENYL)-4-(4-TRIFLUOROMETHOXYPHENOXY)PIPERIDINE OR SALT THEREOF DHPS, PAH, HPD KCNH2 174/4885FPR2 3807/4885PROKR1 4301/4885
US-20070219374-A1 Method of Producing Aminophenol Compounds PAH, CYP1A1, CYP1B1 KCNH2 3236/4885FPR2 848/4885PROKR1 3094/4885
US-10252995-B2 Method for producing 1-(4-hydroxyphenyl)-4-(4-trifluoromethoxyphenoxy)piperidine or salt thereof DHPS, PAH, HPD KCNH2 174/4885FPR2 3807/4885PROKR1 4301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.